Cargando…
Transmitted Drug Resistance Mutations in Antiretroviral-Naïve Injection Drug Users with Chronic HIV-1 Infection in Iran
The growing incidence and transmission of drug resistant HIV-1 strains due to widespread use of antiretroviral therapy (ART) can jeopardize the success of first-line ART. While there is a known moderate prevalence of transmitted drug resistance (TDR) among newly infected Iranians, no data exist abou...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4427455/ https://www.ncbi.nlm.nih.gov/pubmed/25962088 http://dx.doi.org/10.1371/journal.pone.0126955 |
_version_ | 1782370732262555648 |
---|---|
author | Memarnejadian, Arash Menbari, Shahoo Mansouri, Seyed Ali Sadeghi, Leila Vahabpour, Rouhollah Aghasadeghi, Mohammad Reza Mostafavi, Ehsan Abdi, Mohammad |
author_facet | Memarnejadian, Arash Menbari, Shahoo Mansouri, Seyed Ali Sadeghi, Leila Vahabpour, Rouhollah Aghasadeghi, Mohammad Reza Mostafavi, Ehsan Abdi, Mohammad |
author_sort | Memarnejadian, Arash |
collection | PubMed |
description | The growing incidence and transmission of drug resistant HIV-1 strains due to widespread use of antiretroviral therapy (ART) can jeopardize the success of first-line ART. While there is a known moderate prevalence of transmitted drug resistance (TDR) among newly infected Iranians, no data exist about the rate of these primary resistance mutations among the ART-naïve, chronically infected individuals who are, in fact, the main candidates for ART initiation. To address this issue, we collected blood samples from 40 ART-naïve injection drug-users (IDUs) with chronic HIV-1 infection (seroconversion time ranging from 2 to 9 years) living in Sanandaj, Iran, followed by sequencing of the protease and reverse-transcriptase regions from their HIV-1 genome. Phylogenetic analyses of the sequenced regions revealed that all samples were CRF35_AD. Transmitted resistance mutations were interpreted as surveillance drug-resistant mutations (SDRMs) based on the world health organization (WHO) algorithm. The frequency of SDRMs to any class of antiretroviral drugs was 15%, which included mutations to nucleoside reverse transcriptase inhibitors (NRTIs, 10%), with M41L and M184V as the most common (5%), and non-nucleoside reverse transcriptase inhibitors (NNRTIs, 5%), with K103N as the only detected mutation (5%). Although not in the WHO SDRMs list, several minor protease inhibitor resistant mutations listed in the International Antiviral Society-USA panel were identified, of which M36I, H69K, L89M/V/I (each one 100%) and K20R/T (92.5%) can be considered as polymorphic signatures for CRF35_AD.The relatively high rate of TDR mutations in our study raises concerns about the risk of treatment failure in chronically infected IDUs of Sanandaj city. These results suggest that routine resistance testing should be considered before the therapy initiation in this area. Additional surveillance studies are required to generalize this deduction to other cities of Iran. |
format | Online Article Text |
id | pubmed-4427455 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-44274552015-05-21 Transmitted Drug Resistance Mutations in Antiretroviral-Naïve Injection Drug Users with Chronic HIV-1 Infection in Iran Memarnejadian, Arash Menbari, Shahoo Mansouri, Seyed Ali Sadeghi, Leila Vahabpour, Rouhollah Aghasadeghi, Mohammad Reza Mostafavi, Ehsan Abdi, Mohammad PLoS One Research Article The growing incidence and transmission of drug resistant HIV-1 strains due to widespread use of antiretroviral therapy (ART) can jeopardize the success of first-line ART. While there is a known moderate prevalence of transmitted drug resistance (TDR) among newly infected Iranians, no data exist about the rate of these primary resistance mutations among the ART-naïve, chronically infected individuals who are, in fact, the main candidates for ART initiation. To address this issue, we collected blood samples from 40 ART-naïve injection drug-users (IDUs) with chronic HIV-1 infection (seroconversion time ranging from 2 to 9 years) living in Sanandaj, Iran, followed by sequencing of the protease and reverse-transcriptase regions from their HIV-1 genome. Phylogenetic analyses of the sequenced regions revealed that all samples were CRF35_AD. Transmitted resistance mutations were interpreted as surveillance drug-resistant mutations (SDRMs) based on the world health organization (WHO) algorithm. The frequency of SDRMs to any class of antiretroviral drugs was 15%, which included mutations to nucleoside reverse transcriptase inhibitors (NRTIs, 10%), with M41L and M184V as the most common (5%), and non-nucleoside reverse transcriptase inhibitors (NNRTIs, 5%), with K103N as the only detected mutation (5%). Although not in the WHO SDRMs list, several minor protease inhibitor resistant mutations listed in the International Antiviral Society-USA panel were identified, of which M36I, H69K, L89M/V/I (each one 100%) and K20R/T (92.5%) can be considered as polymorphic signatures for CRF35_AD.The relatively high rate of TDR mutations in our study raises concerns about the risk of treatment failure in chronically infected IDUs of Sanandaj city. These results suggest that routine resistance testing should be considered before the therapy initiation in this area. Additional surveillance studies are required to generalize this deduction to other cities of Iran. Public Library of Science 2015-05-11 /pmc/articles/PMC4427455/ /pubmed/25962088 http://dx.doi.org/10.1371/journal.pone.0126955 Text en © 2015 Memarnejadian et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Memarnejadian, Arash Menbari, Shahoo Mansouri, Seyed Ali Sadeghi, Leila Vahabpour, Rouhollah Aghasadeghi, Mohammad Reza Mostafavi, Ehsan Abdi, Mohammad Transmitted Drug Resistance Mutations in Antiretroviral-Naïve Injection Drug Users with Chronic HIV-1 Infection in Iran |
title | Transmitted Drug Resistance Mutations in Antiretroviral-Naïve Injection Drug Users with Chronic HIV-1 Infection in Iran |
title_full | Transmitted Drug Resistance Mutations in Antiretroviral-Naïve Injection Drug Users with Chronic HIV-1 Infection in Iran |
title_fullStr | Transmitted Drug Resistance Mutations in Antiretroviral-Naïve Injection Drug Users with Chronic HIV-1 Infection in Iran |
title_full_unstemmed | Transmitted Drug Resistance Mutations in Antiretroviral-Naïve Injection Drug Users with Chronic HIV-1 Infection in Iran |
title_short | Transmitted Drug Resistance Mutations in Antiretroviral-Naïve Injection Drug Users with Chronic HIV-1 Infection in Iran |
title_sort | transmitted drug resistance mutations in antiretroviral-naïve injection drug users with chronic hiv-1 infection in iran |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4427455/ https://www.ncbi.nlm.nih.gov/pubmed/25962088 http://dx.doi.org/10.1371/journal.pone.0126955 |
work_keys_str_mv | AT memarnejadianarash transmitteddrugresistancemutationsinantiretroviralnaiveinjectiondruguserswithchronichiv1infectioniniran AT menbarishahoo transmitteddrugresistancemutationsinantiretroviralnaiveinjectiondruguserswithchronichiv1infectioniniran AT mansouriseyedali transmitteddrugresistancemutationsinantiretroviralnaiveinjectiondruguserswithchronichiv1infectioniniran AT sadeghileila transmitteddrugresistancemutationsinantiretroviralnaiveinjectiondruguserswithchronichiv1infectioniniran AT vahabpourrouhollah transmitteddrugresistancemutationsinantiretroviralnaiveinjectiondruguserswithchronichiv1infectioniniran AT aghasadeghimohammadreza transmitteddrugresistancemutationsinantiretroviralnaiveinjectiondruguserswithchronichiv1infectioniniran AT mostafaviehsan transmitteddrugresistancemutationsinantiretroviralnaiveinjectiondruguserswithchronichiv1infectioniniran AT abdimohammad transmitteddrugresistancemutationsinantiretroviralnaiveinjectiondruguserswithchronichiv1infectioniniran |